{
    "clinical_study": {
        "@rank": "18206", 
        "arm_group": {
            "arm_group_label": "P7170", 
            "arm_group_type": "Experimental", 
            "description": "Patients will receive study drug on a daily basis until disease progression or unacceptable toxicity in sequential cohorts following accelerated titration design."
        }, 
        "brief_summary": {
            "textblock": "Clinical study of oral PI3K/mTOR inhibitor P7170 in patients with advanced refractory solid\n      tumors. The primary objective is to determine the maximum tolerated dose and dose limiting\n      toxicity of oral PI3K/mTOR inhibitor P7170 in patients with advanced refractory solid tumors"
        }, 
        "brief_title": "Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Refractory Solid Tumors", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "An open label multicentric Phase 1 study of oral PI3K/mTOR inhibitor P7170 in patients with\n      advanced refractory solid tumors.The study will follow an Accelerated Titration Design (ATD)\n      with 100% dose increments until significant toxicity as described below; followed by\n      standard dose titration with 40% dose increments. Dose and schedule (alternate dosing\n      regimen eg. OD, BID, intermittent) will be determined by the dose escalation outlined in the\n      protocol and considering pharmacokinetics of the study drug determined from earlier cohorts."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients having histologically and/or cytologically confirmed non-haematological\n             malignancy that is metastatic or unresectable and for which standard\n             curative/palliative treatment does not exist or is no longer effective or is not\n             tolerated by patient.\n\n          -  Patients of either sex, of all races and ethnic groups, and more than 18 years of\n             age.\n\n          -  ECOG (Eastern Cooperative Oncology Group) performance status less than 2.\n\n          -  Patients with life expectancy of at least 4 months.\n\n          -  Patients with measurable or evaluable disease per Response Evaluation Criteria In\n             Solid Tumors (RECIST) version 1.1.\n\n          -  Patients must have adequate organ and marrow function as defined below:\n\n          -  Absolute neutrophil count more than equal to 1500/cmm\n\n          -  Platelets more than equal 100,000/cmm\n\n          -  Total bilirubin within normal limits of the institution.\n\n          -  AST/ALT less than equal 2.5 X institutional upper limit of normal (ULN) or less than\n             equal 5 X institutional upper limit of normal (ULN) in the presence of liver\n             metastases\n\n          -  Creatinine less than equal 1.5 X institutional upper limit of normal (ULN)\n\n          -  Women of childbearing potential and men willing to agree to use adequate\n             contraception (hormonal or barrier method of birth control; abstinence) prior to\n             study entry, during the duration of study participation and for at least 4 weeks\n             after withdrawal from the study, unless they are surgically sterilised.\n\n          -  Ability to understand and the willingness to provide a written informed consent\n             document.\n\n        Exclusion Criteria:\n\n          1. Patients who have received any prior chemotherapy, radiotherapy, biologic/targeted\n             anti-cancer therapy or surgery within 4 weeks (3 months for monoclonal antibodies,\n             radioactive monoclonal antibodies or any radio- or toxin- immunoconjugates) before\n             study drug administration and have not recovered (to < Grade 1) from the toxic\n             effects from any prior therapy.\n\n          2. Patients having received any other investigational agents within 4 weeks prior to the\n             date of enrolment and have not recovered completely (to < Grade 1) from the side\n             effects of the earlier investigational agent.\n\n          3. Patients with known brain metastases (except for patients who have previously-treated\n             CNS metastases, are asymptomatic, and have had no requirement for steroids or\n             anti-seizure medication for two months prior to first dose of study drug.)\n\n          4. Patients with a history of myocardial infarction or uncontrolled cardiac dysfunction\n             during the previous 6 months.\n\n          5. Patients with diabetes mellitus requiring insulin therapy at screening or patients\n             with clinically significant diabetic complications, such as neuropathy, retinopathy,\n             peripheral vascular disease or nephropathy.\n\n          6. Clinically significant medical condition of malabsorption, inflammatory bowel\n             disease, or chronic diarrheal condition that might affect the absorption of the\n             investigational agent.\n\n          7. Patients on chronic anticoagulation treatment. Prophylactic anticoagulation with\n             low-molecular heparin is allowed.\n\n          8. Patients with inter-current illness including, but not limited to ongoing or\n             clinically significant active infection, symptomatic congestive heart failure,\n             unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social\n             situations that would limit compliance with study requirements.\n\n          9. Patients with a known history of allergic reaction to any other medication considered\n             to be clinically significant by the investigator.\n\n         10. Women who are pregnant or nursing.\n\n         11. Patients with immune deficiency and at increased risk of lethal infections, for\n             example, known h/o HIV, HBV or HCV."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 20, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01762410", 
            "org_study_id": "P7170/70/11"
        }, 
        "intervention": {
            "arm_group_label": "P7170", 
            "description": "Patients will receive study drug on a daily basis for twenty-one  days according to the dose and schedule specified for a particular cohort of therapy. This 21 day administration will define a treatment cycle. Patients may receive consecutive treatment cycles until evidence of disease progression, intolerance of therapy, death or withdrawal from the protocol as specified.", 
            "intervention_name": "P7170", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Sirolimus", 
                "Everolimus"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Advanced refractory solid tumors", 
        "lastchanged_date": "June 3, 2014", 
        "location": [
            {
                "contact": {
                    "email": "elkhouei@usc.edu", 
                    "last_name": "Anthony El-Khoueiry, MD", 
                    "phone": "323-865-3967"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "USC Norris Comprehensive Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Anthony El-Khoueiry, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gurgaon", 
                        "country": "India", 
                        "state": "Haryana", 
                        "zip": "122001"
                    }, 
                    "name": "Medanta Duke Research Institute (MDRI)"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nagpur", 
                        "country": "India", 
                        "state": "Maharashtra"
                    }, 
                    "name": "Central India Cancer Research Institute"
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madurai", 
                        "country": "India", 
                        "state": "Tamil Nadu", 
                        "zip": "625107"
                    }, 
                    "name": "Meenakshi Mission Hospital & Research Centre"
                }, 
                "status": "Active, not recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "India"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label Multicentric Phase 1 Study of Oral PI3K/mTOR Inhibitor P7170 in Patients With Advanced Refractory Solid Tumors.", 
        "overall_contact": {
            "email": "alan.hatfield@piramal.com", 
            "last_name": "Dr Alan K Hatfield, MD", 
            "phone": "+91 22 3027 5002", 
            "phone_ext": "5002"
        }, 
        "overall_contact_backup": {
            "email": "Sandesh.Sawant@piramal.com", 
            "last_name": "Dr Sandesh Sawant", 
            "phone": "+91 22 3027 5130", 
            "phone_ext": "5130"
        }, 
        "overall_official": {
            "affiliation": "University of Southern California", 
            "last_name": "Anthony El-Khoueiry, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "India: Drugs Controller General of India"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Patients will receive study drug on a daily basis for twenty-one  days according to the dose and schedule specified for a particular cohort of therapy. Toxicities observed in Cycle 1 will be considered for dose limiting toxicity (DLT) and Maximum tolerated dose (MTD)determination.", 
            "measure": "Maximum tolerated dose", 
            "safety_issue": "Yes", 
            "time_frame": "End of Cycle 1 (i.e. 21 Days)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01762410"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The toxic effects of the drug would be assessed from adverse events, vital signs and by clinically significant changes in the laboratory evaluations.", 
                "measure": "Number of subject with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Until disease progression or unacceptable toxicity (expected to be 4-6 months)"
            }, 
            {
                "description": "The effect of dose for AUC0-t, AUC0-inf and Cmax. Tmax and T1/2 will be given as patient-wise narratives at each dose level.", 
                "measure": "Pharmacokinetic profile(Cmax,Tmax and AUC)", 
                "safety_issue": "No", 
                "time_frame": "Until disease progression or unacceptable toxicity (expected to be 4-6 months)"
            }, 
            {
                "description": "Plasma samples will be used for analysis of exploratory biomarkers that are found in plasma and levels of which are likely to change in response to P7170 administration", 
                "measure": "Activity of P7170 based on selected biomarkers", 
                "safety_issue": "No", 
                "time_frame": "Until disease progression or unacceptable toxicity (expected to be 4-6 months)"
            }, 
            {
                "description": "Evaluation of Response: Clinical responses will be presented patient wise for different dose levels.", 
                "measure": "Objective response", 
                "safety_issue": "No", 
                "time_frame": "Until disease progression or unacceptable toxicity (expected to be 4-6 months)"
            }
        ], 
        "source": "Piramal Enterprises Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Piramal Enterprises Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}